SHANGHAI & PRINCETON, N.J.
LianBio, a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced the launch of its proposed initial public offering of its American depositary shares (“ADSs”). LianBio has filed a registration statement on Form S-1 with the Securities and Exchange Commission (“SEC”) to offer 20,312,500 ADSs to the public. In addition, LianBio intends to grant the underwriters a 30-day option to purchase up to an additional 3,046,875 ADSs. The initial public offering price is expected to be between $15.00 and $17.00 per share. LianBio has applied to list on the Nasdaq Global Market under the ticker symbol “LIAN.”
Goldman Sachs & Co. LLC, Jefferies LLC and BofA Securities, Inc. are acting as joint bookrunning managers for the proposed offering. Raymond James is acting as lead manager for the proposed offering.
The proposed offering will be made only by means of a prospectus. A copy of the preliminary prospectus relating to the proposed offering may be obtained from Goldman Sachs & Co. LLC, Attn: Prospectus Department, 200 West Street, New York, New York 10282, Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, New York 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com, and BofA Securities, Inc., Attn: Prospectus Department, 200 North College Street, 3rd Floor, Charlotte, North Carolina, 28255-0001, or by email at dg.prospectus_requests@bofa.com.
A registration statement relating to the proposed sale of these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211020005515/en/
CONTACT
For investor inquiries, please contact:
Elizabeth Anderson, VP Communications and Investor Relations
E: elizabeth.anderson@lianbio.com
T: +1 646 655 8390
For media inquiries, please contact:
Katherine Smith, CanaleComm
E: katherine.smith@canalecomm.com
T: +1 619 849 5378
